We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

SUBSCRIBE: Print / eNewsletter

Tositumomab Effective for Low-Grade Follicular Lymphoma

Jul 1, 2000
Volume: 
9
  • Follicular Lymphoma

 

ASCO—Tositumomab (Bexxar), an investigational antibody-based radioim-munotherapy agent, has been shown to be effective as first-line treatment of advanced-stage, low-grade follicular lymphoma, Mark Kaminski, MD, said at the 36th Annual Meeting of the American Society of Clinical Oncology, New Orleans.

The study was conducted at the University of Michigan Comprehensive Cancer Center, where Dr. Kaminski is professor of hematology/oncology and director of the leukemia/lymphoma program.

The phase II study enrolled 76 patients with previously untreated stage III/IV CD20+ follicular lymphoma. Virtually all of the patients (74 of 76, 97%) responded to treatment, and 58 patients (76%) had a complete response. In addition, 84% of patients with evidence of lymphoma at the molecular level at the start of the trial achieved molecular remissions, some lasting as long as 3 years.

“We are extremely excited by these findings, which showed remarkable response rates and molecular remissions ongoing beyond 3 years,” Dr. Kamin-ski said. Molecular remissions are seldom seen with chemotherapy in low-grade lymphoma, and appear to coincide with prolonged, durable responses, he added.

Furthermore, he noted, “these results demonstrate the potential of this treatment to change the prognosis for patients with low-grade lymphoma, a disease without a known cure.”

Patients had either follicular small-cleaved-cell lymphoma (71%) or follicular mixed-cell lymphoma (29%), and the majority (70%) had stage IV disease.

Patients first received a single intravenous dosimetric dose of 450 mg of unlabeled tositumomab, followed by 35 mg of tositumomab radiolabeled with 5 mCi of iodine 131. Whole body gamma counts were used to determine the radioactive clearance. These data were then used to calculate a patient-specific therapeutic dose designed to deliver 75 cGy to the whole body. The therapeutic dose was administered on day 7; patients again received an infusion of unlabeled antibody, followed by tositumomab containing the therapeutic dose of iodine 131.

Molecular Remissions

Polymerase chain reaction (PCR) analyses were conducted to test for detectable signs of disease—t(14;18 translocation)—in blood and marrow among all patients before and every 6 months after therapy.

Of the 37 patients who had molecular signs of lymphoma before treatment, 31 (84%) achieved molecular remissions when measured again later. About 60% of these patients are projected to remain in molecular and complete remission for at least 3 years.

Patients tolerated tositumomab treatment well. Moderate, reversible myelo-suppression was seen. Nadirs typically occurred 4 to 7 weeks after therapy. Grade 4 neutropenia occurred in 5% of patients, and no grade 4 thrombocytopenia was noted. No patients required hematologic supportive care.

Sixty-two percent of patients developed human antimouse antibodies (HAMA) in a median of 38 days, with 41% of patients developing HAMA within 13 days. Of those patients seroconver-ting within the first 2 weeks of therapy, about two thirds experienced flu-like symptoms clearly associated with HAMA, which resolved in a few days.

“A single treatment with iodine 131 tositumomab is highly effective as first-line therapy for follicular lymphoma and results in durable clinical and molecular remissions,” Dr. Kaminski concluded.

In more than 30 years, he noted, the survival rates of low-grade lymphoma patients have not changed when standard chemotherapy has been used. “This trial produced a 97% response rate and superior progression-free survival of 59% at 3 years. These results strongly suggest we have a highly effective new therapy that can help these patients early in the course of this indolent disease.”

Related Articles

  • Duvelisib Granted Priority Review for R/R CLL/SLL and FL
  • PET Imaging Helps to Predict FL Recurrence Risk
  • Previously Unrecognized Variant of FL Described
  • Umbralisib: Early Efficacy, Safety in FL, CLL, More
  • Investigating CAR T-Cell Therapy in Patients With DLBCL, FL, and Other Lymphomas

Resource Topics rightRail

  • Resource Topics
  • Partner Content
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

Oncology Vol 32 No 4
Apr 15, 2018 Vol 32 No 4
Digital Edition
Subscribe
Connect with Us
  • Twitter
  • Facebook
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.